Afami-cel’s BLA Filing Remains On Track for Q4 2022; ADP-A2M4N7X19’s IND Submission Planned by YE 2022; Precision’s Clinical Updates Expected in June 2022; Adaptimmune and Precision Q1 2022 Earnings Summaries
On Monday, May 9, Adaptimmune held their Q1 2022 earnings call (press release / webcast) highlighting afami-cel’s (autologous MAGE-A4 SPEAR-T; formerly ADP-A2M4) anticipated BLA filing in Q4 2022, while discussing anticipated milestones for their MAGE-A4 franchise. On the same day, Precision BioSciences reported their Q1 2022 financial results (press release) confirming multiple planned clinical updates for June 2022. Below, Celltelligence provides insights on Adaptimmune’s vector supply strategy, while discussing at which conference Precision may present their clinical updates.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.